FAQs
1. Can Parkinson’s disease affect younger people?
Yes, while Parkinson’s disease is more common in older adults, a small percentage of people develop symptoms before age 50. This is known as young-onset Parkinson’s disease.
2. Is Parkinson’s disease fatal?
Parkinson’s disease itself is not considered fatal. However, complications from advanced symptoms, such as falls, swallowing difficulties, or infections can be serious and may contribute to reduced life expectancy in some individuals. Overall, people with Parkinson’s often have a near-normal lifespan.
3. Can Parkinson’s disease be prevented?
There is currently no proven way to prevent Parkinson’s disease. Some research suggests that regular exercise and certain lifestyle factors may reduce risk, but no definitive preventive measures have been established.
Reference
1. Kalia, L. V., & Lang, A. E. (2015). Parkinson’s disease. The lancet, 386(9996), 896-912.
2. Goetz, C. G. (2011). The history of Parkinson’s disease: early clinical descriptions and neurological therapies. Cold Spring Harbor perspectives in medicine, 1(1), a008862.
3. De Lau, L. M., & Breteler, M. M. (2006). Epidemiology of Parkinson’s disease. The Lancet Neurology, 5(6), 525-535.
4. Trist, B. G., Hare, D. J., & Double, K. L. (2019). Oxidative stress in the aging substantia nigra and the etiology of Parkinson’s disease. Aging cell, 18(6), e13031.
5. Gepshtein, S., Li, X., Snider, J., et al. (2014). Dopamine function and the efficiency of human movement. Journal of cognitive neuroscience, 26(3), 645-657.
6. Dirkx, M. F., & Bologna, M. (2022). The pathophysiology of Parkinson’s disease tremor. Journal of the Neurological Sciences, 435, 120196.
7. Berardelli, A., Rothwell, J. C., Thompson, P. D., et al. (2001). Pathophysiology of bradykinesia in Parkinson’s disease. Brain, 124(11), 2131-2146.
8. Berardelli, A., Sabra, A. F., & Hallett, M. (1983). Physiological mechanisms of rigidity in Parkinson’s disease. Journal of Neurology, Neurosurgery & Psychiatry, 46(1), 45-53.
9. Palakurthi, B., & Burugupally, S. P. (2019). Postural instability in Parkinson’s disease: a review. Brain sciences, 9(9), 239.
10. Ricciardi, L., Bologna, M., Morgante, F., et al. (2015). Reduced facial expressiveness in Parkinson’s disease: A pure motor disorder?. Journal of the neurological sciences, 358(1-2), 125-130.
11. Manes, J. L., Kurani, A. S., Herschel, E., et al. (2023). Premotor cortex is hypoactive during sustained vowel production in individuals with Parkinson’s disease and hypophonia. Frontiers in human neuroscience, 17, 1250114.
12. Suttrup, I., & Warnecke, T. (2016). Dysphagia in Parkinson’s disease. Dysphagia, 31(1), 24-32.
13. Zham, P., Raghav, S., Kempster, P., et al. (2019). A kinematic study of progressive micrographia in Parkinson’s disease. Frontiers in neurology, 10, 403.
14. Fullard, M. E., Morley, J. F., & Duda, J. E. (2017). Olfactory dysfunction as an early biomarker in Parkinson’s disease. Neuroscience bulletin, 33, 515-525.
15. Lin, Y. Q., & Chen, S. D. (2018). RBD: a red flag for cognitive impairment in Parkinson’s disease?. Sleep Medicine, 44, 38-44.
16. Stocchi, F., & Torti, M. (2017). Constipation in Parkinson’s disease. International review of neurobiology, 134, 811-826.
17. Djamshidian, A., & Friedman, J. H. (2014). Anxiety and depression in Parkinson’s disease. Current treatment options in neurology, 16, 1-13.
18. Meireles, J., & Massano, J. (2012). Cognitive impairment and dementia in Parkinson’s disease: clinical features, diagnosis, and management. Frontiers in neurology, 3, 88.
19. Tai, Y. C., & Lin, C. H. (2020). An overview of pain in Parkinson’s disease. Clinical parkinsonism & related disorders, 2, 1-8.
20. Friedman, J. H., Beck, J. C., Chou, K. L., et al. (2016). Fatigue in Parkinson’s disease: Report from a multidisciplinary symposium. NPJ Parkinson’s disease, 2(1), 1-6.
21. Sakakibara, R., Kishi, M., Ogawa, E., et al. (2011). Bladder, Bowel, and Sexual Dysfunction in Parkinson′ s Disease. Parkinson’s Disease, 2011(1), 924605.
22. Gomperts, S. N. (2016). Lewy body dementias: dementia with Lewy bodies and Parkinson disease dementia. Continuum: Lifelong Learning in Neurology, 22(2), 435-463.
23. Atik, A., Stewart, T., & Zhang, J. (2016). Alpha‐synuclein as a biomarker for Parkinson’s disease. Brain pathology, 26(3), 410-418.
24. Valle, J. (2025). Biofilm-associated proteins: from the gut biofilms to neurodegeneration. Gut Microbes, 17(1), 2461721.
25. Del Tredici, K., & Braak, H. (2013). Idiopathic Parkinson’s disease: staging an α-synucleinopathy with a predictable pathoanatomy. In Madame Curie Bioscience Database [Internet]. Landes Bioscience.
26. Vázquez-Vélez, G. E., & Zoghbi, H. Y. (2021). Parkinson’s disease genetics and pathophysiology. Annual review of neuroscience, 44(1), 87-108.
27. Brown, T. P., Rumsby, P. C., Capleton, A. C., et al. (2006). Pesticides and Parkinson’s disease—is there a link?. Environmental health perspectives, 114(2), 156-164.
28. Taylor, K. M., Saint-Hilaire, M. H., Sudarsky, L., et al. (2016). Head injury at early ages is associated with risk of Parkinson’s disease. Parkinsonism & related disorders, 23, 57-61.
29. Pagano, G., Ferrara, N., Brooks, D. J., et al. (2016). Age at onset and Parkinson disease phenotype. Neurology, 86(15), 1400-1407.
30. Ren, X., & Chen, J. F. (2020). Caffeine and Parkinson’s disease: multiple benefits and emerging mechanisms. Frontiers in Neuroscience, 14, 602697.
31. Crizzle, A. M., & Newhouse, I. J. (2006). Is physical exercise beneficial for persons with Parkinson’s disease?. Clinical Journal of Sport Medicine, 16(5), 422-425.
32. Bega, D., Kuo, P. H., Chalkidou, A., et al. (2021). Clinical utility of DaTscan in patients with suspected Parkinsonian syndrome: a systematic review and meta-analysis. npj Parkinson’s Disease, 7(1), 43.
33. Martin, W. W., Miles, M., Zhong, Q., et al. (2020). Is levodopa response a valid indicator of Parkinson disease?. Movement disorders: official journal of the Movement Disorder Society, 10-1002.
34. Tambasco, N., Romoli, M., & Calabresi, P. (2018). Levodopa in Parkinson’s disease: current status and future developments. Current neuropharmacology, 16(8), 1239-1252.
35. Cánovas, A. A., Piudo, R. L., Ruiz-Espiga, P. G., et al. (2014). Dopaminergic agonists in Parkinson’s disease. Neurología (English Edition), 29(4), 230-241.
36. Jost, W. H. (2022). A critical appraisal of MAO-B inhibitors in the treatment of Parkinson’s disease. Journal of Neural Transmission, 129(5), 723-736.
37. Heumann, R., Moratalla, R., Herrero, M. T., et al. (2014). Dyskinesia in Parkinson’s disease: mechanisms and current non‐pharmacological interventions. Journal of neurochemistry, 130(4), 472-489.
38. Hariz, M., & Blomstedt, P. (2022). Deep brain stimulation for Parkinson’s disease. Journal of internal medicine, 292(5), 764-778.
39. Kwakkel, D. G., De Goede, C. J. T., & Van Wegen, E. E. H. (2007). Impact of physical therapy for Parkinson’s disease: a critical review of the literature. Parkinsonism & related disorders, 13, S478-S487.
40. Sturkenboom, I. H., Graff, M. J., Hendriks, J. C., et al. (2014). Efficacy of occupational therapy for patients with Parkinson’s disease: a randomised controlled trial. The Lancet Neurology, 13(6), 557-566.
41. Miller, N., Deane, K. H., Jones, D., et al. (2011). National survey of speech and language therapy provision for people with Parkinson’s disease in the United Kingdom: therapists’ practices. International Journal of Language & Communication Disorders, 46(2), 189-201.
42. Coune, P. G., Schneider, B. L., & Aebischer, P. (2012). Parkinson’s disease: gene therapies. Cold Spring Harbor perspectives in medicine, 2(4), a009431.
43. Parmar, M., Grealish, S., & Henchcliffe, C. (2020). The future of stem cell therapies for Parkinson disease. Nature Reviews Neuroscience, 21(2), 103-115.
44. Sola, P., Krishnamurthy, P. T., Kumari, M., et al. (2022). Neuroprotective approaches to halt Parkinson’s disease progression. Neurochemistry international, 158, 105380.
45. van der Marck, M. A., Bloem, B. R., Borm, et al. (2013). Effectiveness of multidisciplinary care for Parkinson’s disease: a randomized, controlled trial. Movement disorders, 28(5), 605-611.